A Retrospective Comparison of Postoperative Tumor Necrosis Factor-α Inhibitor Continuation versus Ustekinumab Switch in Crohn’s Disease: Reset or Switch?
In patients undergoing surgery during TNFi treatment, there was no statistically significant difference between postoperative UST switching and TNFi continuation.
Authors
- Masaki Ominami (ORCID: https://orcid.org/0000-0002-9692-0420)
- Yuji Nadatani (ORCID: https://orcid.org/0000-0001-7081-8746)
- Shusei Fukunaga (ORCID: https://orcid.org/0000-0002-9336-8271)
- Rieko Nakata (ORCID: https://orcid.org/0000-0001-9977-7239)
- Koji Fujimoto (ORCID: https://orcid.org/0009-0004-7768-2553)
- Hirotsugu Maruyama (ORCID: https://orcid.org/0000-0002-8728-8101)
- Yasuhiro Fujiwara (ORCID: https://orcid.org/0009-0008-7303-1699)
- Koji Otani (ORCID: https://orcid.org/0000-0001-9075-6415)
- Shuhei Hosomi (ORCID: https://orcid.org/0000-0002-8808-5672)
- Fumio Tanaka (ORCID: https://orcid.org/0000-0002-9186-1249)
- Yu Nishida (ORCID: https://orcid.org/0000-0003-3369-5059)
- Yumie Kobayashi (ORCID: https://orcid.org/0000-0002-5747-6697)
Institutions
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1159/000549403
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- EA Pharma Co., Ltd.
- Daiichi-Sankyo
- Astellas Pharma
- Otsuka Pharmaceutical